CARY, NC--(Marketwire - Sep 7, 2011) - Cornerstone Therapeutics Inc. (
"I am delighted to have Ken join the Cornerstone team and look forward to the leadership he will provide in the Company's execution of its commercial strategy," said Craig Collard. "Ken's experience in specialty markets, and his proven track record, will enhance our ability to grow our core products and to acquire and commercialize new products as we strive to become a leader in the respiratory and hospital markets."
Mr. McBean joins Cornerstone from Covidien plc, where he held the position of Vice President and General Manager of Specialty Pharmaceuticals from March 2009 until May 2011. At Covidien, Mr. McBean was responsible for executing a successful turnaround of the company's branded pharmaceutical products division. Prior to Covidien, Mr. McBean co-founded and headed commercial and corporate development for a number of Canadian-based pharmaceutical start-ups. In addition, he was formerly the Vice President of Marketing and Commercial Development for Biovail Pharmaceuticals and its predecessor company, DJ Pharma, in the US. His earlier career involved various US and global positions at Glaxo Wellcome and Marion Merrell Dow in commercial strategy, product management, market research, and sales. Mr. McBean holds a BS in Business from Kansas State University.
About Cornerstone Therapeutics
Cornerstone Therapeutics Inc. (
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein, other than statements of historical fact, including statements regarding the progress and timing of our product development programs and related trials, our strategy and our future operations and opportunities, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the results of preclinical studies and clinical trials with respect to our products under development, our ability to satisfy FDA and other regulatory requirements, our ability to enter into strategic licensing, product acquisition, collaboration or co-promotion transactions on favorable terms, if at all, and the other factors described in Item 1A (Risk Factors) of our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the SEC) on March 3, 2011 and in our subsequent filings with the SEC. In addition, the statements in this press release reflect our expectations and beliefs as of the date of this release, and these statements should not be relied upon as representing our views as of any other date and do not reflect the potential impact of any acquisitions, mergers, dispositions, business development transactions, joint ventures or investments that we may make or enter into. We anticipate that subsequent events and developments will cause our expectations and beliefs to change. However, while we may elect to update these forward-looking statements publicly at some point in the future, we specifically disclaim any obligation to do so, whether as a result of new information, future events or otherwise, except as required by law.